Influenza Vaccine Market Share

North America Market Insights

The global market of influenza vaccine market is dominated by the North America region and is projected to hold a market share of 40.6% by 2037. High government spending leverages research and development in the influenza vaccine efficiency. Insurance coverage is expanded to ensure better patient accessibility and scalability of the market growth. For instance, the Canadian Universal Healthcare expanded its coverage to approximately 92%, which enables high market demand.

Demographic switch is one of the leading factors that address the aged population is at a higher risk of vaccination for influenza in North America. Apart from the government mandate of compulsory vaccination in paediatrics elevated the demand for influenza vaccine within North America has increased. A technologically sound market of North America experienced high adoption of the cell-based vaccines and quadrivalent vaccines that achieve higher patient outcomes.

The U.S.  is the largest market for influenza vaccines within North America. According to the report of the Centers for Disease Control and Prevention, more than 69% of the adult population of the U.S. gets vaccinated and creating a high demand for the adjuvanted vaccine. The rise of the aging population in the U.S. is one of the important growth-driving factors for the market. Government spending has expanded that reached to fund allocation of approximately USD 4.5 billion in 2024. Medicaid coverage for the senior citizens and low-income groups of people ensured 100% coverage, which increased the market demand. 70 % of the U.S. vaccine dosage is given based on the quadrivalent vaccines that ensure better protection and achieve better patient outcomes.

Asia Pacific Market Insights

The Asia Pacific region is the emerging region in the global influenza vaccine market and is anticipated to hold a market share of 22.7% by 2037, with the fastest CAGR of 8.6%. A heavy government investment is conducted within Asia Pacific to conduct vaccine programming and reduce the health risk outbreaks. Seasonal outbreak of influenza is the most frequent threat faced by the Asia Pacific region, which creates a high demand for vaccines in the concerned market.

Urbanization, change within the climatic conditions, and density of the population are the key factors behind the rise of influenza in the Asia Pacific that creating a significant need for influenza vaccines. Healthcare advancement spending has expanded by approximately 9.5% of growth each year, that enhanced better research and development in influenza vaccine performance.

China is the highest revenue-earning country in the influenza vaccine market within the Asia Pacific. Over 1.2 million incidences are addressed in China each year, which has elevated the demand for the influenza vaccine. Dependency on the import of vaccines is reduced by China and elevating the market as the global vaccine hub, that expanded the market growth of influenza vaccines.  Domestic manufacturing of influenza vaccine directed the market in price reduction and offered affordable treatment that ensures better patient accessibility. The government initiated a fund allocation of over USD 2.5 billion under the scheme of Healthy China 2030, which was targeted to cover more than 95 million high-risk patients.

Government Investment & Policy for Influenza Vaccine, 2025

Europe Market Insights

A steady growth of the influenza vaccine market in Europe is experienced and expected to hold a market share of 28.5% by 2037. The government mandate by the EU Joint Procurement Agreement is directed to secure over 450 million doses each year to control the outbreak of the flu, which resulted in market scalability. As per the mandate, free vaccine doses are distributed to senior citizens of Europe to control health risks. The presence of advanced health infrastructure and a developed environment for technological adoption directed the EU market to adopt cell-based vaccines. As per the data of EMA, over 30% of the vaccine dosage is given through cell-based vaccines. Allocation of approximately €2.4 billion is considered by the EU Health Fund to elevate research and development within the influenza vaccine performance.

Germany is dominating the market in Europe. The government showed a sincere approach to controlling the health risk of influenza and expanded its spending to provide vaccine doses to the patients. STIKO free shot policy is undertaken by Germany to ensure 92% adult population coverage with the vaccine of influenza vaccine. This enhanced the market demand for the influenza vaccine and directed the scope of revenue-generating streams to flourish. Government funding is received by the companies to provide vaccine trials. For instance, BioNTech received USD 198.5 million from EU funding to provide an mRNA vaccine trial.